Date Headline
Jul 18, 2017 09:15 AM TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology
Jun 27, 2017 09:15 AM TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer
Jun 22, 2017 09:18 AM TapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors
Jun 14, 2017 09:55 AM TapImmune to Present at 2017 Biotechnology Innovation Organization International Convention
May 31, 2017 04:05 PM TapImmune Provides First Quarter 2017 Corporate and Clinical Update
May 18, 2017 10:07 AM TapImmune to Provide First Quarter 2017 Business Update Conference Call and Webcast
May 01, 2017 09:15 AM Richard Kenney, MD, FACP, Joins TapImmune to Lead the Clinical Development Program
Apr 28, 2017 04:05 PM TapImmune Announces Change in Management and Board of Directors
Apr 27, 2017 12:55 PM Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space
Apr 19, 2017 08:30 AM NetworkNewsWire Announces Publication Highlighting Advances in Cancer Therapy